How clinical data strategy shapes CGT success. Miguel Forte explores the role of geography, operations and trial design in generating meaningful data.

CGT investment is expanding beyond therapeutics. Explore why investors are backing the tools, platforms and technologies powering the industry.

What makes a biotech company fundable in 2026? Leading investors reveal the science, data, manufacturing and strategy milestones that drive funding decisions.

The Investment Summit opens with Christiaan Engstrom, Founder of BLPN, sharing perspectives on capital, strategy and the evolving future of advanced therapies investment.

Biotech funding is evolving. Explore alternative capital models, structured liquidity and new investor types shaping how emerging companies fund innovation.

Great science isn’t enough. Learn why commercial strategy, pricing and market access are key to turning breakthrough therapies into investable biotech.